| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 631 companies in the Biotechnology industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 8, 2026 | TARA Protara Therapeutics, Inc. | Zummo Jacqueline | Chief R&D Officer | Sell | 1,134 | $5.40 | $6,123.60 | -1.2% | - | - | |
| Apr 8, 2026 | ACET Adicet Bio, Inc. | Orbimed Advisors LLC67 | 10% Owner | Sell | 104,658 | $6.45 | $674,847.06 | -60.8% | - | - | |
| Apr 8, 2026 | ADPT Adaptive Biotechnologies Corporation | Rubinstein Julie84 | President And COO | Sell | 69,061 | $14.34 | $990,503.43 | -3.8% | - | - | |
| Apr 8, 2026 | WHWK Whitehawk Therapeutics, Inc. | Lennon David James | Chief Executive Officer | Sell | 260,427 | $3.45 | $899,537.86 | -12.5% | - | - | |
| Apr 8, 2026 | ADPT Adaptive Biotechnologies Corporation | Robins Chad M63 | CEO And Chairman | Sell | 120,595 | $14.65 | $1,766,839.09 | -2.7% | - | - | |
| Apr 7, 2026 | LPCN Lipocine Inc. | Higuchi John W. | Director | Buy | 40,000 | $2.03 | $81,200.00 | +24.4% | - | - | |
| Apr 7, 2026 | CORT Corcept Therapeutics Incorporated | Guyer William45 | Chief Development Officer | Sell | 20,000 | $40.97 | $819,400.00 | -90.0% | - | - | |
| Apr 6, 2026 | ZLAB Zai Lab Limited | Du Ying79 | Chairperson &CEO | Sell | 2,653 | $20.45 | $54,248.54 | -0.2% | - | - | |
| Apr 6, 2026 | LPCN Lipocine Inc. | Higuchi John W. | Director | Buy | 123,000 | $2.05 | $252,150.00 | +301.5% | - | - | |
| Apr 6, 2026 | ZLAB Zai Lab Limited | Amado Rafael65 | See Remarks | Sell | 2,739 | $20.45 | $56,007.07 | -4.6% | - | - | |
| Apr 6, 2026 | ZLAB Zai Lab Limited | Edmondson Frazor Titus III55 | Chief Legal Officer | Sell | 1,224 | $20.45 | $25,028.35 | -5.0% | - | - | |
| Apr 6, 2026 | ZLAB Zai Lab Limited | Smiley Joshua L58 | See Remarks | Sell | 3,017 | $20.45 | $61,691.62 | -2.5% | - | - | |
| Apr 6, 2026 | HALO Halozyme Therapeutics, Inc. | Torley Helen60 | President And CEO | Sell | 10,000 | $63.50 | $634,981.60 | -0.6% | - | - | |
| Apr 6, 2026 | PTCT Ptc Therapeutics, Inc. | Boulding Mark Elliott55 | Exec. VP And CLO | Sell | 2,265 | $69.45 | $157,293.27 | -1.1% | - | - | |
| Apr 6, 2026 | LPCN Lipocine Inc. | Patel Mahesh V. | Chief Executive Officer | Buy | 25,000 | $2.03 | $50,750.00 | +18.4% | - | - | |
| Apr 6, 2026 | ZLAB Zai Lab Limited | Chen Yajing55 | Chief Financial Officer | Sell | 853 | $20.45 | $17,442.14 | -2.6% | - | - | |
| Apr 6, 2026 | BCYC Bicycle Therapeutics Plc | Skynner Michael76 | Chief Scientific Officer | Sell | 2,404 | $4.94 | $11,877.14 | -0.7% | - | - | |
| Apr 6, 2026 | VOR Vor Biopharma Inc. | Ra Capital Management, L.P.53 | Director, 10% Owner | Sell | 849,257 | $17.10 | $14,518,963.47 | -3.4% | - | - | |
| Apr 6, 2026 | BCYC Bicycle Therapeutics Plc | Hannay Michael Charles Ferguson83 | Chief Prod &Supply Chain Off | Sell | 1,772 | $4.93 | $8,735.66 | -0.9% | - | - | |
| Apr 6, 2026 | BCYC Bicycle Therapeutics Plc | Thompson Travis Alvin82 | Chief Financial Officer | Sell | 901 | $4.93 | $4,438.19 | -0.7% | - | - | |
| Apr 6, 2026 | BCYC Bicycle Therapeutics Plc | Perry Jennifer Scott | Chief Operating Officer | Sell | 1,408 | $4.94 | $6,961.75 | -0.5% | - | - | |
| Apr 6, 2026 | NTHI Neonc Technologies Holdings, Inc. | Heshmatpour Amir F | President | Buy | 25,000 | $6.14 | $153,398.00 | +0.4% | - | - | |
| Apr 6, 2026 | BCYC Bicycle Therapeutics Plc | Lee Kevin75 | Chief Executive Officer | Sell | 7,683 | $4.94 | $37,963.77 | -0.6% | - | - | |
| Apr 2, 2026 | PTCT Ptc Therapeutics, Inc. | Golden Lee Scott45 | EVP &Chief Medical Officer | Sell | 829 | $67.99 | $56,363.71 | -1.0% | +24.6% | - | |
| Apr 2, 2026 | ADPT Adaptive Biotechnologies Corporation | Rubinstein Julie84 | President And COO | Sell | 38,120 | $14.53 | $553,693.00 | -4.1% | +41.5% | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.